The search for alternative methods to mitigate the drawbacks associated with wet 36 laboratory drug discovery has been a major challenge in drug design and has limited 37 the options available in the fight against most Neglected Tropical Diseases (NTDs) 38 such as helminthiasis. We investigated the binding affinities of some approved drugs 39 to Ascaris suum mitochondrial rhodoquinol fumarate reductase enzyme (MRFR),an 40 essential enzyme for ascaris survival, and the possibility of repurposing these drugs 41 as antihelmintic agents using in silico molecular docking and in vitro paralysis and 42 mortality times of fifteen selected front runners.Two hundred approved drugs were 43 selected from ZINC ® database based on bioactivity scores while MRFR(PDB code, 44 3vra) was obtained from the Protein Data Bank (PDB). Both were prepared using 45 AutoDock tools v.1.5.6 and Chimerav.1.9.The docking protocol was validated by 46 computationally reproducing the binding of atpenin to MRFR. The selected approved 47 drugs and the receptor were docked using AutoDockVina v. 4.0. The docking results 48 were analyzed using PyMoL v. 1.4.1.The paralysis and mortality times of the 49 identified frontrunners against Pheretima posthuma were determined in vitro and 50 synergistic testings were done by the checkerboard method. Fifteen drugs had 51 binding free energies between -7.825 to 11.025 kcal/mol while four of these drugs 52 (mefloquine, doxycycline, mepacrine and proguanil) emerged as major frontrunners 53 by both in silico and in vitro assessments. The paralysis and mortality times of the 54 four drugs were between 0.33-0.50 hr as against 1.80-2.36 hr for albendazole. They 55
Introduction

82
The fortuitous nature, enormous cost and huge time invested in traditional drug 83 discovery and development is a major factor that has fueled the inertia in most 84 pharmaceutical companies to engage in research into new chemical entities. This is 85 a consequence of the unpredictability of these researches hence results often do not 86 justify the effort. 87 This scenario has mostly affected the neglected tropical and orphan disease 88 domains. It is so due to the limited number of sufferers and the demography that 89 stratifies them to the resource-poor nations [13] . 90 As a fall out of this, pharmaceutical majors located in regions with the technology 91 and wherewithal do not find it attractive to direct research into these areas due to 92 marginal profit prospects. 93 Helminthiasis, a major Neglected Tropical Disease (NTD) has long been identified by 94 the World Health Organization (WHO) as a disease with very high morbidity rate and 95 cognitive deficit especially in school-aged children [20, 3] . The prevalence is mostly 96 confined to the tropical and subtropical regions where there still exists infrastructural 97 deficit; poor sanitation; use of untreated fecal matter as fertilizers and subsisting bare 98 soil defecation [1] . 99 In addition, no new antihelmintic agents have been added to the list in the past 100 decade with gradual development of resistance to the standard treatments being 101 reported [17, 15] . 102 Drug repurposing has recorded major milestones in several treatment landscapes 103 hence this technique has been considered a veritable tool to achieve this objective in 104 antihelmintic sphere. other drug discovery landscapes gave impetus for the employment of this technique 116 in this study. Prominent among such studies is the work of Uzochukwu, et al., [18] 117 which revealed the potentials of some approved drugs as antihelmintic agents.
119
This study investigated the antihelmintic potential of some approved drugs using 120 Ascaris suum mitochondrial rhodoquinol fumarate reductase enzyme as target. The 121 in vitro paralysis and mortality times of the frontrunners using the ascaris surrogate,
122
Pheretima posthuma were determined.
123
Results
126
On the basis of bioactivity scores similarity of the approved drugs to atpenin, the in-127 house drug database was sorted and one hundred drugs were selected. And the 128 docking protocol was validated by superimposition of the experimental atpenin A5 on 129 the atpenin from docking which showed a near perfect fit (Fig 1) . The post docking analysis yielded two hundred drugs(including their isomers) with 135 binding energies within the range of atpenin (-7.825 kcal/mol).
136
Out of this list, fifteen drugs with the closest binding energies to atpenin were 137 selected as frontrunners.
138
This result is presented in Table 1 . Four out of the fifteen frontrunner drugs were found to exploit the same binding 144 pocket and interacted with the same amino acid residues within the receptor site The synergistic testing produced the greatest activity (optimal fixed dose) at the 6:4 181 ratio of doxycycline and mepacrine (Fig 6 and 7) . This combination produced is usually considered the one with the best interaction and affinity therefore is predicted 191 to have the best activity. The binding energies generated from docking predicted 192 potential antihelmintic activity of some of the approved drugs that were docked.
193
The four major frontrunners, mefloquine, doxycycline, proguanil and mepacrine showed 194 better binding affinities than the experimental antihelmintic compound, atpenin as well as 195 the reference antihelmintic drugs, the benzoimidazoles.
197
The expectation is that these four drugs with binding energies between -11.0 to -8.1 198 kcal/mol will have activities that would surpass that of atpenin. Their exploitation of same 199 binding pocket and interaction with same amino acid residues at the receptor site is were prepared in 9 ratios of 5 mg/ml assay concentration (9:1, 8:2, 7:3, 6:4, 5:5, 4:6, 316 3:7, 2:8, 1:9). Paralysis and mortality effect of both drugs separately and when 317 combined were used for the calculation of their combination index using the formula.
318
+ = 319
Where A = Effect of doxycycline, B = Effect mepacrine, AB = Effect of different ratio 320 combinations of doxycycline and mepacrine. When X = 1 (additive interaction), X > 1 321 (synergistic interaction) and X < 1 (antagonistic interaction).
323
Determination of paralysis and mortality times of frontrunners 324 The determination of paralysis and mortality times of frontrunners among the 325 selected approved drugs was evaluated as described by [2] .
326
Five worms of average weight were rinsed with distilled water and placed in 20 ml 327 solution of each drug in a standard petri dish according to the labeled 328 concentrations.
329
The petri dishes were mechanically swirled to ensure the entire worm bodies were 330 covered in the drug solution. The worms were then monitored for paralysis and 331 mortality times and the observations were recorded. This same procedure was 332 replicated in the synergistic testing. Albendazole served as standard reference while 333 distilled water was negative control. Paralysis was assessed as a situation when the 334 worm loses muscular tone and unable to move its body except with vigorous shaking 335 or when pricked with an object while mortality was considered when the worm does 336 not move its body even when placed in water bath at 50 0 C. 
